Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers

Research output: Contribution to journalArticle

3 Citations (Scopus)


© 2016 Informa UK Limited, trading as Taylor & Francis Group.The asbestos induced cancer malignant mesothelioma (MM) is difficult to diagnose and has a poor prognosis. MM is an immunological cancer, therefore autoantibodies may be suitable biomarkers and associated with prognosis. We used Protoarray® microarrays to determine immune responses to 8798 antigens in 10 MM and 10 asbestos exposed controls and developed diagnostic panels using 17 antigens from this. The AUC of these panels were independently tested in these 10 MM patients and controls and in a validation group of 36 controls and 35 MM patients using luminex assays; none of the antigens identified were validated. Immune responses to RAB38 were associated with a better prognosis.
Original languageEnglish
Pages (from-to)551-561
Number of pages11
Issue number6
Publication statusPublished - 2016


Cite this